Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
AMRX filed a notice of proposed sale of up to 50,000 shares of common stock, to be sold through Merrill Lynch at 157 Church St., New Haven, CT, with a notation of NASDAQ as the trading market. The filing also lists prior transactions over the past three months related to equity compensation.
Amneal Pharmaceuticals, Inc. reported that reporting person Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 shares of Amneal Class A common stock. The shares are held through limited liability companies controlled by family trusts.
The acquisition occurred on August 10, 2026 as part of Amneal’s purchase of 100% of Kashiv BioSciences, LLC membership interests. Deal consideration included $375,000,000 in cash (subject to purchase price adjustments) and 28,942,098 Amneal Class A shares. Following this transaction, entities associated with Patel held 61,341,678 Class A shares indirectly.
Tushar Patel filed Amendment No. 6 reporting his beneficial ownership of Amneal Pharmaceuticals Class A common stock. He beneficially owns 61,341,678 shares, representing 17.6% of the Class A common stock outstanding, with sole voting and dispositive power over all of these shares.
The ownership percentage is based on 348,296,017 shares of Class A common stock outstanding as of August 10, 2026 plus 28,942,098 shares issued in connection with Amneal’s acquisition of Kashiv BioSciences. As part of this transaction, Amneal Pharmaceuticals LLC agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to adjustments, and Amneal was required to issue an aggregate of 28,942,098 Amneal Class A shares to the sellers, including Rock Nola, LLC. Rock Nola, whose sole member is a trust controlled by Patel, received 12,763,469 shares, contributing to Patel’s reported beneficial ownership, which also includes shares held by TI SIE 2.
Amneal Pharmaceuticals, Inc. is reported to have completed the acquisition of Kashiv BioSciences, LLC, with consideration that included both cash and stock. A reporting person, Chirag Patel, filed an amended beneficial ownership statement reflecting his updated holdings and the shares he received in connection with this transaction.
Under a Membership Interest Purchase Agreement, Amneal’s subsidiary agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to adjustments, and Amneal agreed to issue an aggregate of 28,942,098 shares of Class A Common Stock to those sellers. Chirag Patel is reported to beneficially own 29,097,645 shares of Class A Common Stock, representing 8.4% of the class, based on 377,238,115 shares outstanding after including the Kashiv-related issuance. His holdings include directly owned shares, stock options, and shares held through trusts and entities CKR Investments, LLC and Shivkan Dynasty, LLC, over which he is described as having sole voting and dispositive power.
Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, with its subsidiary Amneal Pharmaceuticals LLC purchasing 100% of Kashiv’s membership interests. As consideration at closing, Amneal LLC was required to pay the sellers an aggregate of $375,000,000 in cash, and Amneal was required to issue an aggregate of 28,942,098 shares of Class A Common Stock to the sellers, including CKR Dynasty, LLC and Shivkan Holdings, LLC, entities associated with Chintu Patel.
Following these transactions, Chintu Patel is reported as the beneficial owner of 32,576,528 shares of Amneal Class A Common Stock, representing 9.4% of the class, based on 348,296,017 shares outstanding plus the 28,942,098 shares issued in the Kashiv acquisition. The reporting person holds shares directly, through options, and through various trusts and entities over which he has control, with sole voting and dispositive power over all reported shares.
Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026. This equity was received as part of Amneal’s acquisition of Kashiv BioSciences, LLC, alongside cash consideration and other share issuances. Following this transaction, Patel also holds 1,388,521 shares directly and 24,753,252 shares indirectly through family trusts.
Amneal Pharmaceuticals, Inc. director Gautam Patel reported an indirect acquisition of 283,632 shares of Class A common stock on August 10, 2026. The shares were received by limited liability companies managed by him as part of Amneal’s acquisition of Kashiv BioSciences, LLC. Following this transaction, he also reported 1,643,963 shares held directly.
Amneal Pharmaceuticals, Inc. reported that President & Co-CEO Chirag K. Patel, through limited liability companies he manages, acquired 6,381,734 shares of Class A common stock on August 10, 2026. These shares were issued as part of Amneal’s acquisition of Kashiv BioSciences, LLC. After the transactions, Patel is reported as holding 1,393,470 shares directly and additional Class A shares indirectly, including 21,269,420 shares held by family trusts.
AMRX filed a notice of proposed resale of common stock under Rule 144. The planned sale involves 146,403 shares, all acquired as equity compensation on 03/01/2025, 03/03/2025, and 03/04/2025. The filing lists an approximate sale date of 08/12/2026 and indicates trading on NASDAQ.